The purpose of this research is to determine if using Tarlatamab as a maintenance treatment after completing standard chemotherapy and radiation therapy can help prevent cancer from progressing. The study compares two groups of patients – one group receives Tarlatamab while the other continues with standard care after their initial treatment.

During the study, participants receive Tarlatamab through an intravenous infusion at specified intervals. The maximum daily dose is 10 milligrams, and the treatment may continue for up to 24 months. The medication is a biological product, meaning it is derived from living organisms rather than chemical synthesis. Patients will be monitored regularly to assess how well the treatment works and to check for any side effects.

The purpose of the study is to compare the effectiveness of Tarlatamab with a placebo in patients who have not experienced cancer progression after their initial treatment. Participants in the study will receive either Tarlatamab or a placebo, and their health will be monitored over time to assess how well the treatment works in keeping the cancer from progressing. The study will involve regular check-ups and assessments to track the health and progress of the participants.

In addition to Tarlatamab, other medications such as Tocilizumab, Siltuximab, Buclizine Hydrochloride, Paracetamol, Codeine Phosphate, Argipressin, Mannitol, Betamethasone Sodium Phosphate, and Dexamethasone may be used in the study. These medications are used for various supportive care purposes and will be administered as needed. The study aims to provide valuable information on the potential benefits of Tarlatamab for patients with LS SCLC.

The purpose of the study is to evaluate the effectiveness of these medications when used as a follow-up treatment, also known as consolidation therapy, to help prevent the cancer from returning or worsening. Participants in the study will receive either Toripalimab alone, a combination of Toripalimab and Tifcemalimab, or a placebo. The study is designed to compare the outcomes of these different treatment approaches.

During the study, participants will receive the medications through an intravenous (IV) infusion, which means the medicine is given directly into a vein. The study will monitor participants over a period of time to assess their overall survival and how long they remain free from cancer progression. The trial aims to provide valuable information on whether these treatments can improve outcomes for patients with LS-SCLC.

The purpose of this study is to determine if adding Durvalumab to the standard chemotherapy and radiotherapy treatment can improve outcomes for patients with this type of lung cancer. Participants in the study will receive either the standard treatment of chemotherapy and radiotherapy or the same treatment with the addition of Durvalumab. The study will last for a period of 18 months, during which the progress of the disease will be monitored to see if the cancer stops growing or shrinks.

Throughout the study, the safety and tolerability of the treatments will be closely observed. The main goal is to see if the combination of treatments can help patients live longer without the cancer getting worse. Additionally, the study will assess the overall survival rate, the response of the cancer to the treatment, and the quality of life of the participants. This research aims to provide valuable information that could lead to improved treatment options for patients with Limited Disease Small Cell Lung Cancer.

The purpose of the study is to evaluate how effective durvalumab is in maintaining the health of patients after they have received a combination of chemotherapy and radiation therapy, known as thoracic chemoradiotherapy (CRT). The study will compare the outcomes of patients who receive durvalumab with those who are under regular observation without the drug. Patients will receive durvalumab through an intravenous infusion, which means the medication is given directly into a vein. The treatment period can last up to 24 months, depending on how well the patient responds to the therapy.

Throughout the study, patients will have regular check-ups and assessments to monitor their health and the progression of their cancer. These assessments may include imaging tests like MRI or CT scans to evaluate the size and spread of the cancer. The study aims to determine if durvalumab can help extend the time patients live without their cancer getting worse, which is referred to as progression-free survival. Additionally, the study will look at the overall survival of patients and any side effects they may experience from the treatment.

The purpose of the study is to evaluate how well these treatments work together in improving the survival of patients with LS-SCLC. Participants will receive either the combination of Pembrolizumab and Olaparib with chemoradiation therapy or chemoradiation therapy alone. The study will monitor the progression of the disease and overall survival rates. The trial will also assess the safety of the treatments by tracking any side effects experienced by participants.

Participants in the study will undergo regular assessments, including imaging tests like MRI or CT scans, to monitor the cancer’s response to treatment. The study will last for a period of time, during which participants will receive the assigned treatments and attend follow-up visits to evaluate their health and the effectiveness of the therapy. The goal is to determine if the combination of Pembrolizumab and Olaparib can provide better outcomes for patients with LS-SCLC compared to standard treatment alone.